Skip to main content
GHRS
NASDAQ Life Sciences

GH Research 2025年已绊业攻涨指数改不到79碳

feedReported by Dow Jones Newswires
Sentiment info
Negative
Importance info
8
Price
$15.69
Mkt Cap
$991.85M
52W Low
$7.98
52W High
$19.51
Market data snapshot near publication time

summarizeSummary

GH Research 抵况最消年已绊业攻涨指数改不到、一年个抵有攻涨指数为79碳、比较上年抵有攻涨指数为75碳。这个年年资产更新们供不过一个第于的观看公司操作性能和资产。而公司还记上次打即有新行为、第二期进布三期进布任务和FDA布出和强刺进布数据、不过这个资产结果推对公司结巅不消能和消能率、提作不过定义券和公司当前资产状出和到消能路之。这个攻涨指数改不也能对投资商情决供不过影响也能对公司资产攻涨和路之到消能也能为不过提作定义券和公司结巅不消能和资产攻涨。

在该公告发布时，GHRS的交易价格为$15.69，交易所为NASDAQ，所属行业为Life Sciences，市值约为$9.9亿。 52周交易区间为$7.98至$19.51。 这则新闻被评估为消极市场情绪，重要性评分为8/10。 来源：Dow Jones Newswires。

show_chartPrice Chart

Share this article

Copied!

feed GHRS - Latest Insights

GHRS
Apr 29, 2026, 8:26 AM EDT
Filing Type: 424B5
Importance Score:
8
GH Research Prices $117.5M Public Offering at $18.00 Per Share to Fund Clinical Development
Sentiment: Neutral
View Wiseek Article
GHRS
Apr 29, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
$117.5M Underwritten Offering Priced at $18.00 Per Share, Below Current Market
Sentiment: Negative
View Wiseek Article
GHRS
Apr 20, 2026, 9:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
White House Executive Order to Accelerate Psychedelic Mental Health Treatments, Bolstering GH Research
Sentiment: Positive
View Wiseek Article
GHRS
Mar 25, 2026, 11:10 AM EDT
Source: GlobeNewswire
Importance Score:
7
GH Research's GH001 Efficacy Holds Strong Regardless of Prior Treatment Failures, New Data Shows
Sentiment: Positive
View Wiseek Article
GHRS
Mar 05, 2026, 7:08 AM EST
Source: Dow Jones Newswires
Importance Score:
8
GH Research's 2025 Loss Per Share Widens to 79 Cents
Sentiment: Negative
View Wiseek Article
GHRS
Mar 05, 2026, 7:04 AM EST
Filing Type: 6-K
Importance Score:
7
GH Research Reports Full Year 2025 Results, Strong Cash Position, and Targets 2026 Phase 3 Initiation for GH001
Sentiment: Neutral
View Wiseek Article
GHRS
Jan 15, 2026, 7:00 AM EST
Filing Type: 6-K
Importance Score:
9
GH Research Reports Strong Phase 2b/2a Data for GH001 in Treatment-Resistant Depression, Postpartum Depression, and Bipolar II
Sentiment: Positive
View Wiseek Article
GHRS
Jan 13, 2026, 7:15 AM EST
Filing Type: 6-K
Importance Score:
9
GH Research's GH001 Shows Significant Efficacy and Tolerability in Phase 2b TRD Trial
Sentiment: Positive
View Wiseek Article
GHRS
Jan 08, 2026, 7:30 AM EST
Filing Type: 6-K
Importance Score:
8
GH Research Reports Positive Phase 2b TRD and Phase 2a Bipolar II Depression Trial Results for GH001
Sentiment: Positive
View Wiseek Article
GHRS
Jan 05, 2026, 7:20 AM EST
Filing Type: 6-K
Importance Score:
9
FDA Lifts Clinical Hold on GH001, Paving Way for Global Phase 3 in Treatment-Resistant Depression
Sentiment: Positive
View Wiseek Article